BCOP ACTUAL EXAM TEST BANK 300 + NEWEST QUESTIONS AND CORRECT ANSWERS //VERIFIED//GRADED A+//WITH EXPLANATIONS LATEST UPDATE 2026/2027

BCOP ACTUAL EXAM TEST BANK 300 + NEWEST
QUESTIONS AND CORRECT ANSWERS
//VERIFIED//GRADED A+//WITH EXPLANATIONS LATEST
UPDATE 2026/2027
CLL - Age > 65 or younger patients with significant
comorbidities without del 17p/TP53 maintenance
consider lenalidomide for high risk




CLL - Age > 65 or younger patients with significant
comorbidities without del 17p/TP53 relapse/refractory
ibrutinib, idelalisib + R, venetoclax with or without R




CLL - Frail patients with significant comorbidities
without del 17p/TP53
Obinutuzumab + chlorambucil, ibrutinib, ofatumumab +
chlorambucil, rituxan + chlorambucil




CLL - Frail patients with significant comorbidities
without del 17p/TP53 maintenance
consider lenalidomide for high risk

Page 1 of 88

,Frail patients with significant comorbidities without del
17p/TP53 relapsed/refractory
ibrutinib, idelalisib + R, venetoclax with or without R




CLL - With del 17p/TP53
ibrutinib**, HDMP + rituxan, obinutuzumab,
alemtuzumab with or without rituxan




CLL - With del 17p/TP53 relapsed/refractory
ibrutinib, idelalisib + R, venetoclax with or without R




CLL - With del 17p/TP53 maintenance
consider lenalidomide for high risk




NSCLC stage IA
surgery


Page 2 of 88

,NSCLC stage IB
surgery




NSCLC stage IIA
surgery followed by cisplatin doublet




NSCLC stage IIB
surgery followed by cisplatin doublet




NSCLC stage IIIA
surgery followed by cisplatin doublet




NSCLC stage IIIB
surgery followed by cisplatin doublet + XRT




NSCLC stage III consolidation

Page 3 of 88

, durvalumab




NSCLC stage IV PD-LI >50%
pembrolizumab




NSCLC stage IV SCC
cisplatin/gemcitabine
melanoma - Stage I or II
surgery




melanoma - Stage III
nivolumab, ipilumumab




melanoma - BRAF positive Stage III
dabrafenib + trametinib




Page 4 of 88